Apex Biotechnology (TPE:1733) EPS (Basic): NT$1.63 (TTM As of Dec. 2025)

What is Apex Biotechnology EPS (Basic)?

Apex Biotechnology TPE:1733 -0.17% 81 EPS (Basic) is NT$1.63 as of Dec. 2025. GuruFocus rates TPE:1733 with a GF Score™ of 81/100 and a GF Value™ of NT$30.08 (Fairly Valued). The stock has 2 warning signs investors should review.

Apex Biotechnology's basic earnings per share (Basic EPS) for the three months ended in Dec. 2025 was NT$0.50. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$1.63.

Apex Biotechnology's EPS (Diluted) for the three months ended in Dec. 2025 was NT$0.50. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$1.63.

Apex Biotechnology's EPS without NRI for the three months ended in Dec. 2025 was NT$0.50. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was 1.74.

During the past 12 months, Apex Biotechnology's average EPS without NRIGrowth Rate was 37.20% per year. During the past 3 years, the average EPS without NRI Growth Rate was -1.30% per year. During the past 5 years, the average EPS without NRI Growth Rate was 5.40% per year. During the past 10 years, the average EPS without NRI Growth Rate was 15.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Apex Biotechnology's highest 3-Year average EPS without NRI Growth Rate was 219.30% per year. The lowest was -79.30% per year. And the median was -4.90% per year.

Apex Biotechnology (TPE:1733) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Apex Biotechnology EPS (Basic) Related Terms

Apex Biotechnology EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Apex Biotechnology's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apex Biotechnology EPS (Basic) Chart

Apex Biotechnology Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EPS (Basic)

Get a 7-Day Free Trial

2.03

1.82

1.16

1.28

1.63

Apex Biotechnology Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25
EPS (Basic)	Get a 7-Day Free Trial															0.38	0.62	0.29	0.22	0.50

81GF Score

Apex Biotechnology Corp TPE:1733

EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Apex Biotechnology EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Apex Biotechnology's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(162.892	-	0)	/	99.950
	=	1.63

Apex Biotechnology's Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(50.078	-	0)	/	99.950
	=	0.50

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$1.63

Frequently Asked Questions Learn more about EPS (Basic) →

What does a EPS (Basic) of NT$1.63 mean?

Apex Biotechnology (TPE:1733) has a EPS (Basic) of NT$1.63 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Apex Biotechnology and its competitors.

Is Apex Biotechnology's EPS (Basic) too high?

Apex Biotechnology's current EPS (Basic) is NT$1.63. Overall, Apex Biotechnology has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.

How does Apex Biotechnology's EPS (Basic) compare to VRTX and REGN?

Apex Biotechnology's EPS (Basic) of NT$1.63 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EPS (Basic) for a Biotechnology company?

A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EPS (Basic) mean?

A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Apex Biotechnology and its competitors. Apex Biotechnology's current EPS (Basic) is NT$1.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Apex Biotechnology stock overvalued right now?

Based on GuruFocus' analysis, Apex Biotechnology (TPE:1733) is currently considered Fairly Valued. The stock's GF Value™ is NT$30.08, compared to a current price of NT$29.90 — trading 0.6% below its estimated fair value. The current EPS (Basic) is NT$1.63. Apex Biotechnology's overall GF Score™ is 81/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EPS (Basic) calculated?

EPS (Basic) is calculated from a company's financial statements. For Apex Biotechnology (TPE:1733), the current EPS (Basic) is NT$1.63 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Apex Biotechnology (TPE:1733) Overvalued in 2026?

Based on GuruFocus' analysis, Apex Biotechnology stock appears to be undervalued. The current stock price of NT$29.90 is trading 0.6% below its estimated GF Value™ of NT$30.08. GuruFocus considers Apex Biotechnology to be Fairly Valued.

Key valuation signals for TPE:1733:

EPS (Basic): NT$1.63
GF Value™: NT$30.08 vs. price of NT$29.90 (0.6% below fair value)
GF Score™: 81/100 with 2 warning signs

No single metric tells the full story. See the TPE:1733 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Apex Biotechnology Business Description

Industry Healthcare Biotechnology

Comparable Companies TPE:1762 ROCO:4168 TPE:6885 TPE:6657 ROCO:6461 ROCO:6926 ROCO:1777 ROCO:6733 ROCO:6892 ROCO:6808 VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Address Li-Hsin 5th Road, No. 7, Hsinchu Science Park, Hsinchu, TWN, 30078

Website https://www.apexbio.com

Apex Biotechnology Corp is engaged in the research, development, production, manufacturing, and sale of biochemical testing instruments and proprietary test strips, as well as the import and export of products and components related to its core business. Its product offerings include diabetes testing kits, blood uric acid monitoring systems, blood lactate monitoring systems, blood haemoglobin monitoring systems, etc. The company generates maximum revenue from the sale of test strips, and the rest from testing meters, electrodes, and other products. Geographically, it derives maximum revenue from the USA, and the rest from Italy, Austria, Taiwan, China, and other markets.

81GF Score

Get the complete analysis for TPE:1733

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$29.90

Price

NT$30.08

GF Value

View TPE:1733 Analysis

See EPS (Basic) data for all stocks →